# Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

> **NCT02953301** · PHASE2 · COMPLETED · sponsor: **4SC AG** · enrollment: 201 (actual)

## Conditions studied

- Mycosis Fungoides
- Sezary Syndrome
- Lymphoma, T-Cell, Cutaneous

## Interventions

- **DRUG:** resminostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02953301
- **Lead sponsor:** 4SC AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2023-03
- **Final completion:** 2024-08
- **Target enrollment:** 201 (ACTUAL)
- **Last updated:** 2024-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02953301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02953301, "Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02953301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*